HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 655 participants.

Also called NCT04153149

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 655 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04153149
  • EU CT 2023-508366-15-00
Other papers using this trial's data
  • Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B Journal of the American College of Cardiology, 2026-09-22 DOI, PubMed 42669070
  • Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial Nature medicine, 2025-10 DOI, PubMed 40770082, PMC12532587 In the PMC Open Access subset under CC BY.
  • Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy Journal of the American College of Cardiology, 2025-05-27 DOI, PubMed 40099776
  • Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B Journal of the American College of Cardiology, 2025-08-12 DOI, PubMed 40769675
  • Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis Journal of the American College of Cardiology, 2026-09-22 DOI, PubMed 42669069
  • Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial JAMA cardiology, 2026-10-01 DOI, PubMed 42616515, PMC13491237 Not in the PMC Open Access subset.
  • Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial Journal of the American College of Cardiology, 2025-02-25 DOI, PubMed 39566871
  • Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial JAMA cardiology, 2026-10-01 DOI, PubMed 42646924, PMC13670059 Not in the PMC Open Access subset.
  • Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy The New England journal of medicine, 2025-01-02 DOI, PubMed 39213194

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, Croatia, Czechia, Denmark, France, Germany, Hungary, Ireland, Israel, Japan, Latvia, Lebanon, Lithuania, Malaysia, Moldova, Netherlands, Norway, Peru, Poland, Portugal, Saudi Arabia, Slovenia, South Korea, Spain, Sweden, Thailand, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04153149. Randomized; quadruple masking; primary purpose treatment. Start 2019-11-26 (actual); primary completion 2024-05-08 (actual). Results posted on 2025-10-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Condition
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intervention (Drug)
Vutrisiran
Intervention (Drug)
Sterile Normal Saline (0.9% NaCl)
Lead sponsor
Alnylam Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04153149
Content hash
e1f228daa32caf58a527782ad2f43f6f761825e70700e025fe58ddc0da70b362